Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda to Uncover Novel Tumor-specific Regulatory T-cell Targets and Develop Unique Anti-Suppressor-Based Immunotherapies
Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announced today a corporate strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal of validating novel tumor-infiltrating regulatory T-cell (Treg) targets againstwhich Takeda will develop potential therapies.
As a newly established bioscience company spun out of Institut Curie in the field of Treg immune modulation, Egle Therapeutics has assembled a proprietary translational based target discovery engine leveraging patient samples to map out - at the single cell level - unique transcriptomic signatures and targets specific for tumor-infiltrating Treg sub-populations. Capitalizing on these newly identified tumor-infiltrating Treg targets, the company is building a proprietary Treg modulating drug pipeline which also includes computationally designed resurfaced IL-2 proprietary variants, featuring unique mechanism of action to engage or dis-engage Tregs.
Under the terms of the agreement, Egle Therapeutics will lead target validation efforts on a subset targets Egle has identified and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies. Egle Therapeutics will receive an upfront payment and research funding, and will be eligible to receive additional development and sales milestone payments based on the exclusivity of targets selected by Takeda.
Luc Boblet, co-founder and CEO of Egle Tx, commented “We are thrilled to engage with Takeda to fully exploit the great therapeutic potential of inhibiting the most immunosuppressive arm of immunity to restore antitumor immune response. We believe that joining forces would be the most efficient path to successfully develop novel generation of anti-Treg immunotherapies for the benefit of patients.”
“Working with Egle to leverage the unique translational derived patient data bringing tumor-specific Treg targets is an exciting prospect to further advance our immuno-oncology drug discovery efforts,” said Loïc Vincent, Head, Oncology Drug Discovery Unit at Takeda. “Targeting tumor-infiltrating regulatory T-cells to overcome the immune suppression in tumor microenvironments will complement our current immuno-oncology approaches and help advance an exciting portfolio.”
In addition to the funding of the multi-target research collaboration, Takeda will invest €4.6 million in convertible debt through its venture arm, Takeda Ventures, Inc. (“TVI”), to support Egle’s corporate growth and internal programs on IL-2-based Treg modulation. Egle’s flagship program pioneers the dis-engagement of tumor-infiltrating Treg through unique proprietary series of IL-2 variants that act as IL-2 antagonists.
“While the whole competition converges solely on a similar approach to enhance effector T cells by disrupting binding of IL-2 to Tregs, our IL-2 variants conserve intact IL-2 binding to CD25, conferring a unique mechanism of action for starving Treg from endogenous IL-2, while leaving active the CD8+ effector T cell arm of the immune response,” Luc Boblet added. “Takeda’s equity commitment will help Egle’s launch strikingly hit the road building on our excellent scientific foundation.”
About Egle Therapeutics
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur (former co-founder and CEO of PathoQuest, and former co-founder and CEO of H-Immune sold to HifiBio Therapeutics) and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics is developing first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize computationally designed resurfaced cytokines acting as antagonists or as selective Treg-agonists. Egle’s flagship program pioneers dis-engagement of tumor-infiltrating Tregs through a proprietary series of IL-2 variants featuring a unique antagonism mechanism of action.
To find out more about Egle Therapeutics, please visit www.egle-tx.com
Chief Executive Officer
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ingenic Semiconductor Integrates Allegro DVT Encoding IP into Next-Generation Smart-Video System-On-Chip Solutions3.7.2020 12:46:00 CEST | Press release
Allegro DVT, the leading provider of video semiconductor IP solutions, today announced that Ingenic Semiconductor, one of the leading system-on-chip companies in China has integrated the AL-E150 high-performance video encoding IP into its latest generation of Smart Video products. The Smart Video product family from Ingenic Semiconductor features highly integrated Video Processor system-on-chip (SoC) solutions targeted at various video applications such as consumer and professional video surveillance and battery-operated cameras. One of Ingenic latest video processors, includes Allegro DVT’s AL-E150 H.264/HEVC/JPEG encoder to handle compression of multiple video channels at resolutions up to 5Mpixels. This chip is now shipping in mass-volume. Brad Liu, VP of Smart Video BU, Ingenic commented, “With the AL-E150,Allegro DVT is able to offer a multi-format and feature-rich encoder IP which perfectly meets our requirements and represents the best trade-off between silicon area, high-video
Imaweb-IDF Group Completes Its Acquisition of Serinfer3.7.2020 11:16:00 CEST | Press release
Imaweb/IDF Group (“The Group”), one of the largest developers of customer relationship management (“CRM”) solutions and dealership management systems (“DMS”) for the automotive industry in Europe, announced today that it has completed the acquisition of Serinfer Servicios Informáticos S.L. (“Serinfer”), the computer software segment of the Alvariño Group, a Spanish developer, distributor and supplier of DMS for automobile dealers. The Group is backed by Providence Strategic Growth (“PSG”), the growth equity affiliate of premier asset management firm Providence Equity Partners (“Providence”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200703005051/en/ Serinfer develops a range of sophisticated products to address the evolving needs of automobile dealers. Its flagship offering is SERAUTO, a complete DMS solution that works modularly and can also be integrated to the existing technology of any dealership or workshop. SERAUT
Taiwan’s COVID-19 response win applause, friendship from around the world3.7.2020 10:52:00 CEST | Press release
Once considered the most vulnerable to the COVID-19 outbreak because it’s so close to China, Taiwan has turned out to be a model for the world’s fight against the pandemic, thanks to quick decisions and early measures by its government, and to the high standard of the island nation’s public health system and its people. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200703005042/en/ The management of Grand Hotel in Taipei asks its guests to help form Zero on the building’s facade to celebrate no new COVID-19 cases for the sixth day in a row on May 1, 2020. (Hsu Chao-chang, CNA) According to real-time data released on Worldometer (https://www.worldometers.info/coronavirus/), a website tracking global COVID-19 figures, as of June 30, Taiwan, with only 447 cases, ranked 155th among 215 countries in terms of the number of infections. Only three entities with fewer cases have a larger population than Taiwan’s, which currently sta
Northern Data announces new Block.one backed customer3.7.2020 08:27:00 CEST | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), one of the world's largest providers of high-performance computing (HPC) solutions, continues to enjoy a very successful 2020 with the signing of 180 MW of capacity with a new customer. Northern Data's most recent customer is a Bitcoin mining operation backed by Blockchain Powerhouse Block.one with an initial 180 MW volume and an upsize option to 300 MW, which the company signed today and which shall go live in early 2021. Brendan Blumer, CEO of Block.one, says: "Block.one's focus on leveraging EOSIO to bring increased scalability and transparency to the greater blockchain industry led us to Northern Data and their strategic market positioning and strong leadership. We're excited to be collaborating with them to introduce unprecedented Bitcoin mining solutions, powered by EOSIO." Aroosh Thillainathan, CEO of Northern Data AG adds, "We are pleased that Block.one is convinced of our services and that we have won the company as another bl
ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir), a First-in-Class Treatment for HIV in Adults With Few Treatment Options Available2.7.2020 22:39:00 CEST | Press release
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets. Rukobia is a novel attachment inhibitor for the treatment of HIV-1 infection indicated for use in combination with other antiretroviral (ARV) therapies in heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection, who are failing their current ARV regimen due to resistance, intolerance or safety considerations. Significant advances over the past few decades have dramatically improved HIV treatment and for many, HIV is considered a manageable life-long condition. However, HTE adults – which account for approximately 6% of adults living with HIV who are on treatment – have little to no options left due to resistance, tolerability or safety considerations.1 HTE adults are at risk of progressing to AIDS and
Vertex Files Registration Statement for Proposed Initial Public Offering2.7.2020 22:31:00 CEST | Press release
Vertex, Inc.,a leading provider of tax technology and services, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Vertex intends to list its common stock on the NASDAQ Global Market under the ticker symbol “VERX.” Goldman Sachs & Co. LLC and Morgan Stanley are acting as joint lead book-running managers and as representatives of the underwriters for the proposed offering. BofA Securities, Citigroup and Jefferies are also acting as book-running managers and JMP Securities, Stifel, William Blair and CastleOak Securities, L.P. are acting as co-managers for the proposed offering. The proposed offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to these securities may be obtained
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom